• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    N

    Netherlands Pharmacovigilance Centre Lareb

    EST. 1963
    437论文总数
    7,707引用总数

    论文量&引用量时间轴

    机构学者

    论文(437)

    年份
    起
    –
    止
    排序
    1Metoclopramide Use in Nausea and Vomiting of Pregnancy and Risk of Depressive Symptoms As an Adverse Drug Reaction in the Netherlands: A Disproportionality Analysis in a National Spontaneous Reporting Database.
    Maartje Conijn,Miranda van Tuyl,Eugene P van Puijenbroek,Veronique Y F Maas

    BACKGROUND:Metoclopramide is widely used for nausea and vomiting of pregnancy and hyperemesis gravidarum. While it is known to cause depressive symptoms as an adverse drug reaction, it is unclear if pregnancy increases this risk. OBJECTIVE:To assess whether metoclopramide-induced depressive symptoms are more common in pregnant women compared to nonpregnant women. to assess whether metoclopramide-induced depressive symptoms are more common in pregnant women compared to nonpregnant women. METHODS:A disproportionality analysis was performed using the national spontaneous adverse drug reaction reporting system of the Netherlands. All reports of adverse drug reactions associated with metoclopramide concerning women aged 15-50 years were included. Based on Medical Dictionary for Regulatory Activities-coded terms and case narratives, pregnancy status was determined. Cases were defined as reports on depressive symptoms. A case review was performed. Disproportionality in reporting between pregnant and nonpregnant women was evaluated using a reporting odds ratio with 95% confidence interval. For comparison, 2 other antiemetic drugs (ondansetron and meclozine with pyridoxine) were also assessed. RESULTS:Reports of depressive symptoms associated with metoclopramide use were reported more often in pregnant women (21.1%) than in nonpregnant women (3.0%; reporting odds ratio 8.6; 95% confidence interval 3.2-23.2). In pregnancy-related cases, depressive symptoms were reported more often following metoclopramide exposure (21.1%) compared to exposure to other antiemetics (7.3%; reporting odds ratio 3.4; 95% confidence interval 1.2-9.3). In 33.3% of the pregnancy-related cases, suicidality tendency was reported. Depressive symptoms were often accompanied by other mood-related symptoms including anxiety, panic attacks, agitation, and restlessness. CONCLUSIONS:Although a causal relationship cannot be established, metoclopramide exposure during pregnancy was associated with increased reporting of depressive symptoms compared to both nonpregnant women and exposure to other antiemetics during pregnancy. This may be explained by a combination of pregnancy-related factors and the pharmacological mechanism of metoclopramide. Given the frequent co-occurrence of suicidal tendency, awareness of this possible adverse drug reaction is crucial for early recognition and prompt intervention to prevent symptom progression and improve maternal safety.

    2026Journal of the Academy of Consultation-Liaison Psychiatry(2026)
    引用
    AI阅读
    加入学术空间
    2Secondary Data Analysis of Adverse Drug Reactions Reported by Healthcare Professionals and Patients: Interventions to Manage ADRs of ACE Inhibitors and ARBs
    S. H. Spronk, J. T. H. Nielen, L. Heier, N. Jessurun, A. Kant, F. Karapinar -Çarkit

    PurposePrescribing cascades occur when an adverse drug reaction (ADR) of a first medication is treated with a second medication, potentially leading to polypharmacy and harm. While various interventions are recommended to prevent harm, it is unknown which are implemented in daily practice. This study aims to assess the interventions implemented for ADRs of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB).MethodsThis cross-sectional study analysed secondary data from spontaneous ADR reports submitted to the Netherlands Pharmacovigilance Center Lareb. Reports were included if the ADR was suspected to be caused by an ACE inhibitor or ARB and an intervention was documented. The primary outcome was the proportion of ADRs treated with (1) dose reduction, (2) discontinuation of the suspected medication, (3) discontinuation followed by medication to treat the ADR, (4) switching to alternative medication, or (5) addition of marker medication (prescribing cascade). The secondary outcome was the proportion of ADRs resolved at the time of the ADR report.ResultsA total of 902 ADR reports were included. The most frequent intervention was discontinuing the suspected medication, followed by introducing medication to treat the ADR (42.5%), resulting in a large proportion of resolved ADRs (46.5%). However, 11.9% of reports included prescribing cascades, resolving the ADR in only 25.2% of reports.ConclusionUsing real-world pharmacovigilance data, this study offers valuable insights into the treatment of ADRs of ACE inhibitors and ARBs in daily practice. Further research is needed to establish the most effective interventions for specific types of ADRs.

    2026European Journal of Clinical Pharmacology(2026)
    引用
    AI阅读
    加入学术空间
    3Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group
    Florence van Hunsel, Samantha Lane, Dawn Cooper, Taylor Aurelius, Amy Bobbins, Harriet Dickinson,Manfred Hauben, Denise Morris,Eugene van Puijenbroek, Alison Yeomans, Manal Younus, Saad Shakir

    A focus group organised by the Drug Safety Research Unit (DSRU) International Working Group (IWG) on New Developments in Pharmacovigilance discussed current challenges and opportunities in pharmacovigilance (PV), emphasising the need for a multimodal approach in data analysis and accessibility of diverse data sources for drug safety surveillance. Nine participants, selected purposefully for their multisectoral expertise in PV, discussed the value of various data types, including data from clinical trials and real-world data (RWD), each offering distinct strengths and limitations. Key challenges identified included data standardisation, quality variability, technological barriers and ethical concerns, particularly with data derived from social media. Emerging tools such as knowledge graphs were highlighted for their potential to enhance data integration and signal detection, however further research is required. The group also addressed disparities in data access, with particular attention to regulatory restrictions, limited infrastructure in low-resource settings and restricted access to industry-held data. Proposed solutions included fostering greater data transparency, establishing secure data-sharing platforms and forming collaborative consortia to facilitate responsible and ethical data use. Overall, the discussion underscored the need for improved integration, access and methodological rigour to strengthen PV practices and enhance global drug safety monitoring.

    2026Drug Safety(2026)
    引用
    AI阅读
    加入学术空间
    4Editorial: Pandemic Preparedness in Vaccine Safety and Regulation
    Manal M Younus,Florence van Hunsel
    2026Frontiers in drug safety and regulation(2026)
    引用
    AI阅读
    加入学术空间
    5Evaluating COVID-19 Vaccine Masking and Unmasking Methods in Two National Pharmacovigilance Databases
    Oskar Rachwal, Mar Gutiérrez-Lobón, Nuria Sols Cueto, Araceli Nuñez Ventura, Cristina Fernández-Fernández, Florence P. A. M. van Hunsel, Joep H. G. Scholl, María Gordillo-Marañón, Eugène P. van Puijenbroek

    The COVID-19 mass vaccination led to a substantial increase in spontaneous reports submitted to pharmacovigilance (PV) databases, potentially introducing masking effects that could conceal safety signals. To examine the masking effect of COVID-19 vaccines on disproportionality analyses and to compare two unmasking interventions in the Dutch (Lareb database) and Spanish (Farmacovigilancia Española, Datos de Reacciones Adversas, FEDRA) national PV databases: removal of all drug–event combinations (DEC) involving a COVID-19 vaccine versus excluding influential outliers DECs only. The masking effect was explored retrospectively on the basis of the number of signals of disproportionate reporting (SDR). DECs involving a COVID-19 vaccine were excluded using crude and outlier techniques, and reporting odds ratios were recalculated. Subsets of important medical events (IME) were analysed in both databases. Both crude and influential outlier removal methods led to reductions in the number of reports, DECs and SDRs. Both in the Lareb database and FEDRA, crude removal excluded 2.1

    2026Drug Safety(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 437 篇论文

    合作机构(100)

    格罗宁根大学合作论文 29
    乌得勒支大学合作论文 25
    阿姆斯特丹大学合作论文 20
    奈梅亨拉德布大学合作论文 19
    Uppsala Monitoring Centre合作论文 17
    Medisch Spectrum Twente合作论文 15
    Pharmac合作论文 15
    乌得勒支大学医学中心合作论文 14
    维罗纳大学合作论文 12
    格罗宁根大学医学中心合作论文 11

    机构统计